Capital Fund Management S.A. acquired a new position in shares of Ascendis Pharma A/S during the third quarter valued at $2,270,000.

Source: https://www.etfdailynews.com/2023/06/13/ascendis-pharma-a-s-nasdaqasnd-shares-purchased-by-nelson-van-denburg-campbell-wealth-management-group-llc/

On average, equities research analysts predict that Ascendis Pharma A/S will post -10.64 earnings per share for the current year.

Source: https://www.dailypolitical.com/2023/05/15/ascendis-pharma-a-s-nasdaqasnd-sees-significant-decrease-in-short-interest.html

Research analysts forecast that Ascendis Pharma A/S will post -11.03 earnings per share for the current fiscal year.

Source: https://www.etfdailynews.com/2023/03/18/ascendis-pharma-a-s-nasdaqasnd-coverage-initiated-at-stocknews-com/